EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MTAP deletion suppresses T cell function with targetable phosphodiesterase rescue in glioblastoma

Landon J Hansen, Eli Yazigi, A Karim Ahmed, Yu-Chien Shih, Marvin Li, FNU Ruchika, Sai Chandan Reddy, Jackson Miller, Viviana Li, Aanya Shahani, Karolina Woroniecka, Peter E Fecci und 4 weitere

Neuro-Oncology Advances · 13.11.2026

DOI: 10.1093/noajnl/vdag280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 13.11.2026. Verfasst von Landon J Hansen und 15 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) actively suppresses local and systemic immunity, which is a key driver of poor patient outcomes. One of the best-established mechanisms of immune evasion is through adenosine receptor signaling, which increases cyclic adenosine monophosphate (cAMP), altering immune programming. Methylthioadenosine (MTA) is a natural metabolite that increases in the context of methylthioadenosine phosphorylase (MTAP) gene deletion, one of the most frequent alterations in GBM, and is newly identified as immunosuppressive. The aim of this study is to determine whether the immunosuppressive action of MTA is mediated by cAMP and whether this signaling pathway can be modified pharmacologically.

Methods

Immune cell cultures were tested in vitro in the presence of MTA and MTAP knockout cells. Immune cell activation, cytokines, cAMP levels, and phosphodiesterase activity are measured. Mice implanted with WT and MTAP KO tumor cells are monitored for survival and analyzed by flow cytometry and immunohistochemistry.

Results

We demonstrate that MTA increases cAMP, which acts as a negative regulator of T cell cytotoxicity and skews myeloid cells to an immunosuppressive phenotype. A novel drug class of phosphodiesterase activators is able to overcome the effects of MTA by reducing cAMP. Intraperitoneal treatment of orthotopic GBM mouse models with a phosphodiesterase activator, MR-L2, results in enhanced T cell function, improved animal survival, and results in long term immunity.

Conclusion

MTAP deletion in glioblastoma cells contributes to the immunosuppressive microenvironment and pharmacologic phosphodiesterase activation is a viable strategy to enhance the anti-tumor immune response.

Zitieren

APA

Hansen, L. J., Yazigi, E., Ahmed, A. K., Shih, Y., Li, M., Ruchika, F., Reddy, S. C., Miller, J., Li, V., Shahani, A., Woroniecka, K., Fecci, P. E., Brem, H., He, Y., Bettegowda, C., & Jackson, C. M. (2026). MTAP deletion suppresses T cell function with targetable phosphodiesterase rescue in glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdag280

Vancouver

Hansen LJ, Yazigi E, Ahmed AK, Shih Y, Li M, Ruchika F, et al. MTAP deletion suppresses T cell function with targetable phosphodiesterase rescue in glioblastoma. Neuro-Oncology Advances. 2026. doi:10.1093/noajnl/vdag280

BibTeX
@article{Hansen2026,
  author = {Hansen, Landon J and Yazigi, Eli and Ahmed, A Karim and Shih, Yu-Chien and Li, Marvin and Ruchika, FNU and Reddy, Sai Chandan and Miller, Jackson and Li, Viviana and Shahani, Aanya and Woroniecka, Karolina and Fecci, Peter E and Brem, Henry and He, Yiping and Bettegowda, Chetan and Jackson, Christopher M},
  title = {MTAP deletion suppresses T cell function with targetable phosphodiesterase rescue in glioblastoma},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  doi = {10.1093/noajnl/vdag280}
}
Kostenlos starten →